SCHEMBL5886926

SCHEMBL5886926

COC1=CC[CH]C(c2ccc(Oc3ccccc3)cc2)=C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 5/20 0.47
NPC1 O15118 1/20 0.38
GSTP1 P09211 1/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 3/20 0.36
HTT P42858 3/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
NISCH Q9Y2I1 1/20 0.36
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ERN1 O75460 1/20 0.35
CA4 P22748 1/20 0.35
MAOA P21397 2/20 0.35
NR1H2 P55055 1/20 0.35
BAX Q07812 1/20 0.35
MCL1 Q07820 1/20 0.35
KDM1A O60341 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4805626 0.85 CA12 (0.41) NPC1ALDH1A1MEN1MAPTKMT2A
SCHEMBL4808505 0.79 LTA4H (0.37) LTA4HNPC1GSTP1TSHRALDH1A1
SCHEMBL6047596 0.79 ABL1 (0.45) LTA4HNPC1GSTP1ALDH1A1HTT
SCHEMBL4013107 0.78 RELA (0.37) NPC1TSHRALDH1A1MEN1MAPT
SCHEMBL5887472 0.77 PGR (0.41) LTA4HNPC1GSTP1TSHRHTT
SCHEMBL5887269 0.71 LTA4H (0.46) LTA4HNPC1GSTP1TSHRALDH1A1
SCHEMBL3800471 0.70 CA12 (0.39) NPC1ALDH1A1MEN1MAPTKMT2A
SCHEMBL4804654 0.70 ACHE (0.39) NPC1TSHRALDH1A1MEN1KMT2A
SCHEMBL4802145 0.70 AHR (0.41)
SCHEMBL15722134 0.69 LTA4H (0.86) LTA4HNPC1GSTP1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R LTA4H 3106/4885NPC1 1831/4885GSTP1 4210/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R LTA4H 3360/4885NPC1 2930/4885GSTP1 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.